On Tuesday, Shares of Gilead Sciences, Inc. (NASDAQ:GILD), lost -0.40% to $110.56.
For a brief moment, and mostly on Twitter, Gilead Sciences, was buying Achillion Pharmaceuticals.
The speculation of another hepatitis C-related acquisition took off Monday afternoon, sparked by a rumor that Gilead executives canceled a planned Tuesday presentation at a health care investor conference. Earlier Monday, Achillion Pharmaceuticals cancelled its presentation at the same investor conference.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
Shares of Dollar General Corp.(NYSE:DG), declined -0.89% to $73.83, during its last trading session.
The Dollar General Literacy Foundation awarded more than $5.8 million in grants to support adult, family and summer literacy programs to about 720 schools, nonprofits and literacy organizations across the 43 states Dollar General (DG) serves.
“It is exciting to see the impact grants from the Dollar General Literacy Foundation make throughout the country, especially as we cross the $100 million threshold in overall donations and the difference it has made to nearly six million people,” said Rick Dreiling, Dollar General’s chairman and CEO. “The Dollar General Literacy Foundation truly embodies the company’s mission of Serving Others throughout the communities we serve.”
Dollar General Corporation, a discount retailer, provides various merchandise products in the southern, southwestern, midwestern, and eastern United States.
At the end of Tuesday’s trade, Shares of Stratasys, Ltd. (NASDAQ:SSYS), gained 1.19% to $35.68.
Stratasys Asia Pacific, partner of Stratasys Ltd. (SSYS), a leading global provider of 3D printing and additive manufacturing solutions, declared that its long-term collaborator, architect and designer Neri Oxman, has revealed the world’s first 3D printed photosynthetic wearable, embedded with living matter. On the TED2015 stage in Vancouver, Oxman unveiled Mushtari, an artwork 3D printed by Stratasys, and the world’s first wearable combining multi-material additive manufacturing and synthetic biology.
Stratasys Ltd. provides additive manufacturing (AM) solutions for the creation of parts used in the processes of designing and manufacturing products; and for the direct manufacture of end parts.
Finally, UDR, Inc. (NYSE:UDR), ended its last trade with -0.48% loss, and closed at $32.93.
UDR, Inc. (NYSE:UDR), declared the closing of the formerly revealed west coast development joint venture with an initial investment of $136 million comprising of five under construction communities totaling 1,533 homes. The Company is in negotiation to add a sixth asset to the joint venture. The transaction is right away accretive to 2015 FFO.
UDR, Inc. is an independent real estate investment trust. The firm invests in the real estate markets of the United States. It owns, operates, acquires, renovates, develops, redevelops, and manages multifamily apartment communities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
